Nelfinavir Mesylate

Known as: Nelfinavir Monomethane Sulfonate, Sulfonate, Nelfinavir Monomethane, Mesylate, Nelfinavir 
The mesylate salt form of nelfinavir, a synthetic antiviral agent that selectively binds to and inhibits human immunodeficiency virus (HIV) protease… (More)
National Institutes of Health

Related topics

Related topics

17 relations

Narrower (2)

AG 1343Viracept
Acquired Immunodeficiency SyndromeAstemizoleCisaprideDrug Allergy
(More)

Broader (4)

Antiviral AgentsIsoquinolinesNelfinavirSulfonic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
A study explored the pharmacokinetics of tenofovir (300 mg administered once daily) and nelfinavir (1,250 mg twice daily) when… (More)
  • table 1
  • figure 1
Is this relevant?
2005
2005
The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral…
The absolute bioavailability of nelfinavir was determined in 6 healthy volunteers following simultaneous administration of 1250… (More)
  • figure 1
  • figure 2
  • figure 3
  • table II
  • figure 4
Is this relevant?
2001
2001
Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.
Nelfinavir mesylate (Viracept, formally AG1343) is a potent and orally bioavailable human immunodeficiency virus (HIV) type 1… (More)
Is this relevant?
Review
2000
Review
2000
Nelfinavir mesylate.
Nelfinavir is an inhibitor of the HIV-1 and HIV-2 protease, with good in vivo activity in HIV-infected patients. Nelfinavir is… (More)
Is this relevant?
1998
1998
Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.
In vitro studies with human liver microsomes and P450 probe substrates were performed to characterize selectivity and mechanism… (More)
  • table 2
  • table 1
  • figure 1
  • table 3
  • table 4
Is this relevant?
1998
1998
A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.
A phase I/II dose-ranging open-label 28-day monotherapy study of the safety, pharmacokinetics, and antiviral activity of… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.
Nelfinavir mesylate (formerly AG1343) is a potent and selective inhibitor of human immunodeficiency virus (HIV) protease approved… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343… (More)
Is this relevant?
1996
1996
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
Dolasetron mesilate [(2 alpha, 6 alpha, 8 alpha, 9a beta)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-c arboxylate… (More)
Is this relevant?
1988
1988
21-Aminosteroid lipid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils.
U74006F (21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16 alpha-methylpregna-1,4,9(11)-triene-3,20-dione… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?